Lee, D. H., Kim, H. R., Moon, H., Kim, I., Rajasekaran, N., Im, S., Kim, N. Y., Choi, J. Y., Shin, Y., Lee, S. (2025). Phase 2 cohort-2 trial in progress: Vabametkib plus lazertinib for patients with EGFR-mutant NSCLC who developed resistance to 1st-line, 3rd-gen-EGFR TKIs via C-Met dysregulation.. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2025.43.16_suppl.tps8662